

Table 1. Efficacy Outcomes by perampanel dose in patients with POS with/without SGS (Full Analysis Set)

	4 mg (n=43)	6 mg (n=27)	8 mg (n=12)	10 mg (n=2)	12 mg (n=1)
50% Responder Rate, n (%)	40 (93.0)	22 (81.5)	6 (50.0)	0 (0.0)	0 (0.0)
Seizure-freedom Rate, n (%)	26 (60.5)	12 (44.4)	2 (16.7)	0 (0.0)	0 (0.0)
Median Percent Reduction in Seizure Frequency per 28 Days, % (min, max)	100.0 (100.0, -106.7) ^a	91.9 (100.0, -85.5)	45.8 (100.0, -1457.3)	-13.0 (37.4, -63.3)	14.3 (14.3, 14.3)

^an=42

POS, partial-onset seizures; SGS, secondarily generalized seizures; TEAE, treatment-emergent adverse event